3-((4'-Methyl-2'-pivalamido-[4,5'-bithiazol]-2-yl)amino)-propanoic Acid

ID: ALA4574879

PubChem CID: 155561063

Max Phase: Preclinical

Molecular Formula: C15H20N4O3S2

Molecular Weight: 368.48

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1nc(NC(=O)C(C)(C)C)sc1-c1csc(NCCC(=O)O)n1

Standard InChI:  InChI=1S/C15H20N4O3S2/c1-8-11(24-14(17-8)19-12(22)15(2,3)4)9-7-23-13(18-9)16-6-5-10(20)21/h7H,5-6H2,1-4H3,(H,16,18)(H,20,21)(H,17,19,22)

Standard InChI Key:  XGZWWMRJMWUREF-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 25  0  0  0  0  0  0  0  0999 V2000
   21.6489   -5.6955    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   20.9877   -5.2145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.2376   -4.4366    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.0561   -4.4366    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.3102   -5.2145    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1014   -5.4264    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.7374   -4.9095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.4207   -5.3564    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   24.2090   -6.1471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3924   -6.1876    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.7883   -6.7264    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.5764   -7.5135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.1558   -8.0929    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.9439   -8.8842    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.5233   -9.4635    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.1526   -9.0961    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.4676   -3.7292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.1964   -5.4264    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   19.6171   -4.8471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.8290   -4.0558    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   18.8258   -5.0590    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.6139   -5.8502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.2506   -4.4796    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.0387   -5.2709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  1  1  0
  6  5  1  0
  6  7  2  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10  6  1  0
  9 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 14 16  2  0
  4 17  1  0
  2 18  1  0
 18 19  1  0
 19 20  2  0
 19 21  1  0
 21 22  1  0
 21 23  1  0
 21 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4574879

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 368.48

Molecular Weight (Monoisotopic): 368.0977

AlogP: 3.45

#Rotatable Bonds: 6

Polar Surface Area: 104.21

Molecular Species: ACID

HBA: 7

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 4.02

CX Basic pKa: 2.54

CX LogP: 2.83

CX LogD: -0.26

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.72

Np Likeness Score: -1.71

References

1. Tassini S, Langron E, Delang L, Mirabelli C, Lanko K, Crespan E, Kissova M, Tagliavini G, Fontò G, Bertoni S, Palese S, Giorgio C, Ravanetti F, Ragionieri L, Zamperini C, Mancini A, Dreassi E, Maga G, Vergani P, Neyts J, Radi M..  (2019)  Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach †.,  62  (23): [PMID:31729878] [10.1021/acs.jmedchem.9b01416]

Source

Source(1):

• Scientific Literature